SAGE Therapeutics Lands $38,000,000 Series C Round

  • Feed Type
  • Date
    3/13/2014
  • Company Name
    SAGE Therapeutics
  • Mailing Address
    215 First Street Cambridge, MA 02142
  • Company Description
    SAGE Therapeutics’ mission is to make life better for patients with nervous systems diseases by discovering, developing, and delivering important new medicines to the market.
  • Website
    http://www.sagerx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    SAGE plans to use the proceeds of the financing to advance the company’s clinical and preclinical programs in orphan and acute CNS disorders, including status epilepticus.
  • M&A Terms
  • Venture Investor
    OrbiMed Advisors
  • Venture Investor
    Foresite Capital
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Undisclosed